Table 3.
Summary of C-KIT Trials
| Trial | Patients | RR% (CR/PR) |
PFS (month) |
OS | Number (patients) |
Summary |
|---|---|---|---|---|---|---|
| Single Arm Phase 2 Kim KB et al. [52] |
Imatinib mesylate 400 mg bid in advanced unresectable melanoma | 5% | 1.4 | 7.5 months | 21 | Imatinib mesylate demonstrated a response in 1 patient who also had high c-kit expression and alternate splicing variant in c-kit mRNA transcript. |
| Single Arm Phase 2 Carvajal et al. [54] |
Imatinib mesylate 400 mg bid in advanced unresectable melanoma | 16% | 3 | 46.3 weeks |
28 | Imatinib mesylate demonstrated a significant clinical response in subset of patients with cKit mutation and advanced melanomaa |
| Single Arm Phase 2 Guo et al. [53] |
Imatinib mesylate 400 mg daily in metastatic melanoma | 23.3% | 3.5 | 14 months |
43 | Imatinib mesylate demonstrated a significant clinical response in a subset of patients with cKit mutation and metastatic melanomaa |
athe clustering of responses in both trials were seen in patients harboring c-kit mutations at exon 11 or exon 13; c-kit overexpression on IHC without a mutation did not correlate with a response. CR, complete response; OS, overall survival; PFS, progression free survival; PR, partial response; RR, response rate.